» Articles » PMID: 35886870

Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer's Disease Patients

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jul 27
PMID 35886870
Authors
Affiliations
Soon will be listed here.
Abstract

Reelin binds to the apolipoprotein E receptor apoER2 to activate an intracellular signaling cascade. The proteolytic cleavage of reelin follows receptor binding but can also occur independently of its binding to receptors. This study assesses whether reelin proteolytic fragments are differentially affected in the cerebrospinal fluid (CSF) of Alzheimer's disease (AD) subjects. CSF reelin species were analyzed by Western blotting, employing antibodies against the N- and C-terminal domains. In AD patients, we found a decrease in the 420 kDa full-length reelin compared with controls. In these patients, we also found an increase in the N-terminal 310 kDa fragment resulting from the cleavage at the so-called C-t site, whereas the 180 kDa fragment originated from the N-t site remained unchanged. Regarding the C-terminal proteolytic fragments, the 100 kDa fragment resulting from the cleavage at the C-t site also displayed increased levels, whilst the one resulting from the N-t site, the 250 kDa fragment, decreased. We also detected the presence of an aberrant reelin species with a molecular mass of around 500 kDa present in AD samples (34 of 43 cases), while it was absent in the 14 control cases analyzed. These 500 kDa species were only immunoreactive to N-terminal antibodies. We validated the occurrence of these aberrant reelin species in an Aβ42-treated reelin-overexpressing cell model. When we compared the AD samples from genotype subgroups, we only found minor differences in the levels of reelin fragments associated to the genotype, but interestingly, the levels of fragments of apoER2 were lower in ε4 carriers with regards to ε3/ε3. The altered proportion of reelin/apoER2 fragments and the occurrence of reelin aberrant species suggest a complex regulation of the reelin signaling pathway, which results impaired in AD subjects.

Citing Articles

The Inflammation-Induced Dysregulation of Reelin Homeostasis Hypothesis of Alzheimer's Disease.

Reive B, Lau V, Sanchez-Lafuente C, Henri-Bhargava A, Kalynchuk L, Tremblay M J Alzheimers Dis. 2024; 100(4):1099-1119.

PMID: 38995785 PMC: 11380287. DOI: 10.3233/JAD-240088.


Reelin Signaling in Neurodevelopmental Disorders and Neurodegenerative Diseases.

Joly-Amado A, Kulkarni N, Nash K Brain Sci. 2023; 13(10).

PMID: 37891846 PMC: 10605156. DOI: 10.3390/brainsci13101479.


Morphological and biomolecular targets in retina and vitreous from Reelin-deficient mice (Reeler): Potential implications for age-related macular degeneration in Alzheimer's dementia.

Balzamino B, Esposito G, Marino R, Calissano P, Latina V, Amadoro G Front Aging Neurosci. 2022; 14:1015359.

PMID: 36466614 PMC: 9708893. DOI: 10.3389/fnagi.2022.1015359.

References
1.
Krstic D, Rodriguez M, Knuesel I . Regulated proteolytic processing of Reelin through interplay of tissue plasminogen activator (tPA), ADAMTS-4, ADAMTS-5, and their modulators. PLoS One. 2012; 7(10):e47793. PMC: 3474754. DOI: 10.1371/journal.pone.0047793. View

2.
Turk L, Kuang X, Pozzo V, Patel K, Chen M, Huynh K . The structure-function relationship of a signaling-competent, dimeric Reelin fragment. Structure. 2021; 29(10):1156-1170.e6. DOI: 10.1016/j.str.2021.05.012. View

3.
Panpalli Ates M, Karaman Y, Guntekin S, Ergun M . Analysis of genetics and risk factors of Alzheimer's Disease. Neuroscience. 2016; 325:124-31. DOI: 10.1016/j.neuroscience.2016.03.051. View

4.
Lugli G, Krueger J, Davis J, Persico A, Keller F, Smalheiser N . Methodological factors influencing measurement and processing of plasma reelin in humans. BMC Biochem. 2003; 4:9. PMC: 200967. DOI: 10.1186/1471-2091-4-9. View

5.
Koch S, Strasser V, Hauser C, Fasching D, Brandes C, Bajari T . A secreted soluble form of ApoE receptor 2 acts as a dominant-negative receptor and inhibits Reelin signaling. EMBO J. 2002; 21(22):5996-6004. PMC: 137191. DOI: 10.1093/emboj/cdf599. View